Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT study

OBJECTIVE: A previous study demonstrated that non-anthracycline-containing docetaxel plus cyclophosphamide (TC) regimen was inferior to docetaxel, anthracycline and cyclophosphamide (TAC) in neoadjuvant treatment of triple-negative breast cancer (TNBC) and human epidermal growth factor receptor-2-(H...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiaosong, Ye, Guolin, Zhang, Chenfang, Li, Xinzheng, Shen, Kunwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242451/
https://www.ncbi.nlm.nih.gov/pubmed/28174484
http://dx.doi.org/10.21147/j.issn.1000-9604.2016.06.02

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242451/
https://www.ncbi.nlm.nih.gov/pubmed/28174484
http://dx.doi.org/10.21147/j.issn.1000-9604.2016.06.02

Ejemplares similares